US FDA acts against misconduct in drug and device development process
This article was originally published in RAJ Devices
Executive Summary
A year after the US Food and Drug Administration finalised new procedures to prevent noncompliant clinical investigators and others from participating in the development of new drugs and medical devices, the agency is initiating steps to streamline the process further and make it more transparent1.